Endobronchial Valve System Market Growth, Key Companies & Industry Trends

0
172

Endobronchial Valve System Market Overview

Endobronchial Valve System Market is growing at a CAGR of 7% during the forecast period 2024-2031.

Endobronchial valve systems are one-way bronchoscopic valves implanted to occlude airways feeding diseased lung segments most commonly used for bronchoscopic lung volume reduction in severe emphysema and for managing persistent air leaks (bronchopleural/bronchoalveolar fistulas). The public executive summary for the DataM Intelligence report notes the market is growing as clinical adoption increases and regulatory clearances for key valve systems expand.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/endobronchial-valve-system-market

Executive summary

Two commercial valve systems (Pulmonx’s Zephyr and Olympus’s Spiration) have driven much of the clinical and commercial adoption, with Zephyr holding breakthrough/expedited status in the U.S. and Spiration widely used for targeted lobar treatment. The devices differ in shape and mechanism (duckbill vs umbrella), but both offer a minimally invasive alternative to surgical lung-volume reduction in selected emphysema patients and provide an option for persistent air-leak management.

Why the market matters

  • Clinical alternative to surgery: Endobronchial valves let physicians achieve lung-volume reduction with bronchoscopy instead of open surgery for select patients, lowering peri-operative morbidity in appropriately selected cases.
  • Unmet needs in severe emphysema & persistent air leaks: The rising prevalence of COPD/emphysema and variable outcomes with conservative care create a durable addressable population for valve therapies.
  • Device innovation & regulatory momentum: FDA breakthrough designations and approvals have sped clinical uptake and stimulated product development and trials.

Market drivers

Rising adoption for severe emphysema as clinicians seek less-invasive lung-volume reduction options.
Clinical evidence of improved patient outcomes (better lung function, symptomatic relief, improved quality of life in responders) that supports broader use at tertiary centers.
Growing network of specialized interventional pulmonology and stroke/critical-care programs able to perform advanced bronchoscopic procedures.

Restraints & challenges

Procedure-related complications and device migration — these safety issues and case selection complexity limit adoption in some centers.
High device & procedure costs — affordability and reimbursement remain barriers in price-sensitive markets.
Need for robust evidence and appropriate patient selection tools (e.g., collateral ventilation assessment) to predict responders and justify therapy.

Product & segment snapshot

  • Device shape: Umbrella-shaped valves (e.g., Spiration) and duckbill-shaped valves (e.g., Zephyr) are the primary device forms identified in market segmentation.
  • Applications: Emphysema (lung-volume reduction), COPD care, treatment of persistent air leaks and other niche bronchoscopic indications.
  • End-users: Hospitals, specialty pulmonary clinics, academic research centres and ambulatory surgical centres performing bronchoscopic interventions.

Regional outlook

  • North America — largest market: Strong presence of major device makers, high procedure volumes, and concentrated interventional pulmonary expertise make North America the leading region.
  • Asia-Pacific — fastest growing: Expansion of specialized centers and rising awareness of advanced COPD therapies are driving adoption across APAC.
  • Europe, Latin America, MEA: Variable uptake depending on reimbursement, specialist training availability, and regulatory timelines.

Competitive landscape & key players

Major players named on the report page include Pulmonx Corporation (Zephyr) and Olympus / Spiration Valve System — with other device developers and smaller medtech firms active in this endovascular/bronchoscopic niche. Competitive differentiation centres on clinical evidence, valve design (migration resistance, ease of placement/removal), and distribution/clinical training networks.

Recent developments & market context

  • Regulatory milestones: Pulmonx’s Zephyr received breakthrough device recognition and expedited pathways in the U.S., accelerating clinical availability. Olympus’s Spiration also secured approvals for targeted emphysema indications.
  • COVID-19 considerations: Severe COVID-19 pneumonias and related air-leak complications briefly highlighted bronchoscopic valve insertion as a therapeutic option in select cases, impacting clinical demand and case mixes during the pandemic.

 

Search
Categories
Read More
Other
Infrastructure as a Service Market Share in India Sees Strong Growth
India Cloud Infrastructure as a service Market Overview Maximize Market Research is a...
By Poonam Chauhan 2025-04-08 08:49:52 0 1K
Home
How to maintain the wooden desk​ in the company?
How to maintain the wooden desk​ in the company? The maintenance of solid wood office desks...
By Wawa Lee 2025-09-03 05:11:47 0 379
Games
Monopoly GO Flippin’ Fortunes Event: Rewards Guide
Flippin’ Fortunes Event Overview In Monopoly GO, the excitement continues with the new...
By Xtameem Xtameem 2025-09-27 00:11:58 0 79
Other
Europe Basmati Rice Market is projected to reach USD 589.2 million in 2023, with a CAGR of 4.79%
Market Insights As per recent research by MarkNtel Advisors, The Europe Basmati Rice...
By Akio Komatsu 2024-09-11 22:25:03 0 3K
SMG https://sharemeglobal.com